Evidence map›Paper›PMID 38579605›Full record

Trial reportDrug and alcohol dependence2024

A randomized controlled trial of intermittent theta burst stimulation to the medial prefrontal cortex for tobacco use disorder: Clinical efficacy and safety.

Merideth A Addicott, Kaitlin R Kinney, Santiago Saldana, Edward Hak-Sing Ip, Hannah DeMaioNewton, Warren K Bickel, Colleen A Hanlon

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Merideth A AddicottDepartment of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA. Electronic address: maddicot@wakehealth.edu.
Kaitlin R KinneyDepartment of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
Santiago SaldanaDepartment of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
Edward Hak-Sing IpDepartment of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
Hannah DeMaioNewtonDepartment of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
Warren K BickelFralin Biomedical Research Institute, Virginia Tech Carilion School of Medicine, Roanoke, VA 24016, USA.
Colleen A HanlonDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA; BrainsWay, Burlington, MA 01803, USA.

Funding

Translational approaches to TMS treatment development for smokingR01DA044471 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ADDICOTT, MERIDETH A., BICKEL, WARREN K · 2018 to 2021
$2.5M
NIDA NIH HHS R01 DA044471
6 · The paper itself

Abstract

objectiveThis study aimed to evaluate the clinical efficacy and safety of administering intermittent theta burst stimulation (iTBS) to the medial prefrontal cortex for tobacco use disorder.

methodsA randomized sham-controlled trial was conducted, with 38 participants receiving 28 sessions of active (n=25) or sham (n=13) iTBS (2 sessions/day, 600 pulses/session, 110% resting motor threshold, AFz target) along with smoking cessation education (Forever Free © booklets) over 14 visits. Primary outcomes included self-reported cigarette consumption and abstinence, verified by urinary cotinine tests. Secondary outcomes included symptoms of tobacco use disorder, negative mood, and safety/tolerability.

resultsBoth active and sham groups reported reduced cigarette consumption (β = -0.12, p = 0.015), cigarette craving (β = -0.16, p = 0.002), and tobacco withdrawal symptoms (β = -0.05, p < 0.001). However, there were no significant time x group interaction effects for any measure. Similarly, the two groups had no significant differences in urinary cotinine-verified abstinence. Adverse events occurred with similar frequency in both groups.

conclusionThere were no differences in cigarette consumption between the active and sham iTBS groups, both groups decreased cigarette consumption similarly. Further research is needed to compare iTBS to standard high-frequency rTMS and explore the potential differences in efficacy. Despite limitations, this study contributes to experimental design considerations for TMS as a novel intervention for tobacco and other substance use disorders, emphasizing the need for a more comprehensive understanding of the stimulation parameters and target sites.

Indexed as

Prefrontal CortexTobacco Use DisorderTranscranial Magnetic StimulationAdultCotinineCravingFemaleHumansMaleMiddle AgedSmoking CessationSubstance Withdrawal SyndromeTheta RhythmTreatment OutcomeYoung AdultCotinineIntermittent theta burst stimulationMedial prefrontal cortexRandomized controlled trialSmoking cessationTMSTobacco use disorder

Identifiers

PMID38579605
PMCPMC11088513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.